ID   UBC9_HUMAN              Reviewed;         158 AA.
AC   P63279; D3DU69; P50550; Q15698; Q59GX1; Q86VB3;
DT   11-OCT-2004, integrated into UniProtKB/Swiss-Prot.
DT   11-OCT-2004, sequence version 1.
DT   10-MAY-2017, entry version 154.
DE   RecName: Full=SUMO-conjugating enzyme UBC9;
DE            EC=2.3.2.- {ECO:0000269|PubMed:26524494};
DE   AltName: Full=RING-type E3 SUMO transferase UBC9;
DE   AltName: Full=SUMO-protein ligase;
DE   AltName: Full=Ubiquitin carrier protein 9;
DE   AltName: Full=Ubiquitin carrier protein I;
DE   AltName: Full=Ubiquitin-conjugating enzyme E2 I;
DE   AltName: Full=Ubiquitin-protein ligase I;
DE   AltName: Full=p18;
GN   Name=UBE2I; Synonyms=UBC9, UBCE9;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RX   PubMed=8668529; DOI=10.1093/nar/24.11.2005;
RA   Yasugi T., Howley P.M.;
RT   "Identification of the structural and functional human homolog of the
RT   yeast ubiquitin conjugating enzyme UBC9.";
RL   Nucleic Acids Res. 24:2005-2010(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9067428;
RA   Tachibana M., Iwata N., Watanabe A., Nobukuni Y., Ploplis B.,
RA   Kajigaya S.;
RT   "Assignment of the gene for a ubiquitin-conjugating enzyme (UBE2I) to
RT   human chromosome band 16p13.3 by in situ hybridization.";
RL   Cytogenet. Cell Genet. 75:222-223(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Fetal brain;
RX   PubMed=8565643;
RA   Watanabe T.K., Fujiwara T., Kawai A., Shimizu F., Takami S.,
RA   Hirano H., Okuno S., Ozaki K., Takeda S., Shimada Y., Nagata M.,
RA   Takaichi A., Takahashi E., Nakamura Y., Shin S.;
RT   "Cloning, expression, and mapping of UBE2I, a novel gene encoding a
RT   human homologue of yeast ubiquitin-conjugating enzymes which are
RT   critical for regulating the cell cycle.";
RL   Cytogenet. Cell Genet. 72:86-89(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND INTERACTION WITH PARP.
RX   PubMed=9197546; DOI=10.1016/S0378-1119(97)00015-2;
RA   Masson M., Menissier-de Murcia J., Mattei M.-G., de Murcia G.M.,
RA   Niedergang C.P.;
RT   "Poly(ADP-ribose) polymerase interacts with a novel human ubiquitin
RT   conjugating enzyme: hUbc9.";
RL   Gene 190:287-296(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RX   PubMed=8610150; DOI=10.1073/pnas.93.7.2958;
RA   Kovalenko O.V., Plug A.W., Haaf T., Gonda D.K., Ashley T., Ward D.C.,
RA   Radding C.M., Golub E.I.;
RT   "Mammalian ubiquitin-conjugating enzyme Ubc9 interacts with Rad51
RT   recombination protein and localizes in synaptonemal complexes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:2958-2963(1996).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8668125; DOI=10.1007/BF02172913;
RA   Jiang W., Koltin Y.;
RT   "Two-hybrid interaction of a human UBC9 homolog with centromere
RT   proteins of Saccharomyces cerevisiae.";
RL   Mol. Gen. Genet. 251:153-160(1996).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   PubMed=8798754; DOI=10.1074/jbc.271.40.24811;
RA   Wang Z.-Y., Qiu Q., Seufert W., Taguchi T., Testa J.R., Whitmore S.A.,
RA   Callen D.F., Welsh D., Shenk T., Deuel T.F.;
RT   "Molecular cloning of the cDNA and chromosome localization of the gene
RT   for human ubiquitin-conjugating enzyme 9.";
RL   J. Biol. Chem. 271:24811-24816(1996).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Shen Z.;
RL   Submitted (OCT-1995) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9333025; DOI=10.1038/sj.onc.1201301;
RA   Hahn S.L., Criqui-Filipe P., Wasylyk B.;
RT   "Modulation of ETS-1 transcriptional activity by huUBC9, a ubiquitin-
RT   conjugating enzyme.";
RL   Oncogene 15:1489-1495(1997).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11157797; DOI=10.1093/hmg/10.4.339;
RA   Daniels R.J., Peden J.F., Lloyd C., Horsley S.W., Clark K.,
RA   Tufarelli C., Kearney L., Buckle V.J., Doggett N.A., Flint J.,
RA   Higgs D.R.;
RT   "Sequence, structure and pathology of the fully annotated terminal 2
RT   Mb of the short arm of human chromosome 16.";
RL   Hum. Mol. Genet. 10:339-352(2001).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [16]
RP   INTERACTION WITH ADENOVIRUS E1A.
RX   PubMed=8824223; DOI=10.1074/jbc.271.42.25906;
RA   Hateboer G., Hijmans E.M., Nooij J.B.D., Schlenker S., Jentsch S.,
RA   Bernards R.;
RT   "mUBC9, a novel adenovirus E1A-interacting protein that complements a
RT   yeast cell cycle defect.";
RL   J. Biol. Chem. 271:25906-25911(1996).
RN   [17]
RP   INTERACTION WITH SIAH1.
RX   PubMed=9334332; DOI=10.1101/gad.11.20.2701;
RA   Hu G., Zhang S., Vidal M., Baer J.L., Xu T., Fearon E.R.;
RT   "Mammalian homologs of seven in absentia regulate DCC via the
RT   ubiquitin-proteasome pathway.";
RL   Genes Dev. 11:2701-2714(1997).
RN   [18]
RP   INTERACTION WITH AR.
RX   PubMed=10383460; DOI=10.1074/jbc.274.27.19441;
RA   Poukka H., Aarnisalo P., Karvonen U., Palvimo J.J., Jaenne O.A.;
RT   "Ubc9 interacts with the androgen receptor and activates receptor-
RT   dependent transcription.";
RL   J. Biol. Chem. 274:19441-19446(1999).
RN   [19]
RP   INTERACTION WITH FHIT.
RX   PubMed=11085938; DOI=10.1042/bj3520443;
RA   Shi Y., Zou M., Farid N.R., Paterson M.C.;
RT   "Association of FHIT (fragile histidine triad), a candidate tumour
RT   suppressor gene, with the ubiquitin-conjugating enzyme hUBC9.";
RL   Biochem. J. 352:443-448(2000).
RN   [20]
RP   FUNCTION.
RX   PubMed=11451954; DOI=10.1074/jbc.M104214200;
RA   Tatham M.H., Jaffray E., Vaughan O.A., Desterro J.M.P., Botting C.H.,
RA   Naismith J.H., Hay R.T.;
RT   "Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein
RT   substrates by SAE1/SAE2 and Ubc9.";
RL   J. Biol. Chem. 276:35368-35374(2001).
RN   [21]
RP   INTERACTION WITH TFAP2A; TFAP2B AND TFAP2C.
RX   PubMed=12072434; DOI=10.1074/jbc.M202780200;
RA   Eloranta J.J., Hurst H.C.;
RT   "Transcription factor AP-2 interacts with the SUMO-conjugating enzyme
RT   UBC9 and is sumolated in vivo.";
RL   J. Biol. Chem. 277:30798-30804(2002).
RN   [22]
RP   MUTAGENESIS OF 100-ASP-LYS-101.
RX   PubMed=12641448; DOI=10.1021/bi026861x;
RA   Tatham M.H., Chen Y., Hay R.T.;
RT   "Role of two residues proximal to the active site of Ubc9 in substrate
RT   recognition by the Ubc9.SUMO-1 thiolester complex.";
RL   Biochemistry 42:3168-3179(2003).
RN   [23]
RP   INTERACTION WITH SUMO1; SUMO2; SUMO3 AND THE UBLE1A-UBLE1B E1 COMPLEX,
RP   AND MUTAGENESIS OF 13-ARG-LYS-14 AND 17-ARG-LYS-18.
RX   PubMed=12924945; DOI=10.1021/bi0345283;
RA   Tatham M.H., Kim S., Yu B., Jaffray E., Song J., Zheng J.,
RA   Rodriguez M.S., Hay R.T., Chen Y.;
RT   "Role of an N-terminal site of Ubc9 in SUMO-1, -2, and -3 binding and
RT   conjugation.";
RL   Biochemistry 42:9959-9969(2003).
RN   [24]
RP   INTERACTION WITH RANBP2.
RX   PubMed=15378033; DOI=10.1038/nsmb834;
RA   Pichler A., Knipscheer P., Saitoh H., Sixma T.K., Melchior F.;
RT   "The RanBP2 SUMO E3 ligase is neither HECT- nor RING-type.";
RL   Nat. Struct. Mol. Biol. 11:984-991(2004).
RN   [25]
RP   INTERACTION WITH THE PML-RARALPHA ONCOPROTEIN, AND FUNCTION.
RX   PubMed=15809060; DOI=10.1016/j.bbrc.2005.03.052;
RA   Kim Y.E., Kim D.Y., Lee J.M., Kim S.T., Han T.H., Ahn J.H.;
RT   "Requirement of the coiled-coil domain of PML-RARalpha oncoprotein for
RT   localization, sumoylation, and inhibition of monocyte
RT   differentiation.";
RL   Biochem. Biophys. Res. Commun. 330:746-754(2005).
RN   [26]
RP   INTERACTION WITH RANBP2, AND MUTAGENESIS OF PHE-22; VAL-25; VAL-27;
RP   GLU-42; LYS-48; GLU-54; LEU-57; LYS-59 AND ARG-61.
RX   PubMed=15608651; DOI=10.1038/nsmb878;
RA   Tatham M.H., Kim S., Jaffray E., Song J., Chen Y., Hay R.T.;
RT   "Unique binding interactions among Ubc9, SUMO and RanBP2 reveal a
RT   mechanism for SUMO paralog selection.";
RL   Nat. Struct. Mol. Biol. 12:67-74(2005).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16620772; DOI=10.1016/j.abb.2006.03.002;
RA   Li T., Santockyte R., Shen R.-F., Tekle E., Wang G., Yang D.C.H.,
RA   Chock P.B.;
RT   "A general approach for investigating enzymatic pathways and
RT   substrates for ubiquitin-like modifiers.";
RL   Arch. Biochem. Biophys. 453:70-74(2006).
RN   [28]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH SOX4.
RX   PubMed=16631117; DOI=10.1016/j.bbrc.2006.03.194;
RA   Pan X., Li H., Zhang P., Jin B., Man J., Tian L., Su G., Zhao J.,
RA   Li W., Liu H., Gong W., Zhou T., Zhang X.;
RT   "Ubc9 interacts with SOX4 and represses its transcriptional
RT   activity.";
RL   Biochem. Biophys. Res. Commun. 344:727-734(2006).
RN   [29]
RP   INTERACTION WITH HERPESVIRUS 6 IE2.
RX   PubMed=17005699; DOI=10.1128/JVI.00375-06;
RA   Tomoiu A., Gravel A., Tanguay R.M., Flamand L.;
RT   "Functional interaction between human herpesvirus 6 immediate-early 2
RT   protein and ubiquitin-conjugating enzyme 9 in the absence of
RT   sumoylation.";
RL   J. Virol. 80:10218-10228(2006).
RN   [30]
RP   INTERACTION WITH RWDD3, AND SUBCELLULAR LOCATION.
RX   PubMed=17956732; DOI=10.1016/j.cell.2007.07.044;
RA   Carbia-Nagashima A., Gerez J., Perez-Castro C., Paez-Pereda M.,
RA   Silberstein S., Stalla G.K., Holsboer F., Arzt E.;
RT   "RSUME, a small RWD-containing protein, enhances SUMO conjugation and
RT   stabilizes HIF-1alpha during hypoxia.";
RL   Cell 131:309-323(2007).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION OF
RP   KAT5-UBE2I-SENP6 COMPLEX.
RX   PubMed=17704809; DOI=10.1038/sj.onc.1210710;
RA   Cheng Z., Ke Y., Ding X., Wang F., Wang H., Wang W., Ahmed K., Liu Z.,
RA   Xu Y., Aikhionbare F., Yan H., Liu J., Xue Y., Yu J., Powell M.,
RA   Liang S., Wu Q., Reddy S.E., Hu R., Huang H., Jin C., Yao X.;
RT   "Functional characterization of TIP60 sumoylation in UV-irradiated DNA
RT   damage response.";
RL   Oncogene 27:931-941(2008).
RN   [32]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [33]
RP   INTERACTION WITH DNMT1.
RX   PubMed=19450230; DOI=10.1042/BJ20090142;
RA   Lee B., Muller M.T.;
RT   "SUMOylation enhances DNA methyltransferase 1 activity.";
RL   Biochem. J. 421:449-461(2009).
RN   [34]
RP   INTERACTION WITH FOXL2, ROLE IN FOXL2 SUMOYLATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=19744555; DOI=10.1016/j.cellsig.2009.09.001;
RA   Kuo F.T., Bentsi-Barnes I.K., Barlow G.M., Bae J., Pisarska M.D.;
RT   "Sumoylation of forkhead L2 by Ubc9 is required for its activity as a
RT   transcriptional repressor of the steroidogenic acute regulatory
RT   gene.";
RL   Cell. Signal. 21:1935-1944(2009).
RN   [35]
RP   INTERACTION WITH DNM1L, AND FUNCTION IN DNM1L SUMOYLATION.
RX   PubMed=19638400; DOI=10.1096/fj.09-136630;
RA   Figueroa-Romero C., Iniguez-Lluhi J.A., Stadler J., Chang C.R.,
RA   Arnoult D., Keller P.J., Hong Y., Blackstone C., Feldman E.L.;
RT   "SUMOylation of the mitochondrial fission protein Drp1 occurs at
RT   multiple nonconsensus sites within the B domain and is linked to its
RT   activity cycle.";
RL   FASEB J. 23:3917-3927(2009).
RN   [36]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-65, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [37]
RP   INTERACTION WITH HUMAN ADENOVIRUS EARLY E1A PROTEIN.
RX   PubMed=20543865; DOI=10.1038/onc.2010.226;
RA   Yousef A.F., Fonseca G.J., Pelka P., Ablack J.N., Walsh C., Dick F.A.,
RA   Bazett-Jones D.P., Shaw G.S., Mymryk J.S.;
RT   "Identification of a molecular recognition feature in the E1A
RT   oncoprotein that binds the SUMO conjugase UBC9 and likely interferes
RT   with polySUMOylation.";
RL   Oncogene 29:4693-4704(2010).
RN   [38]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [39]
RP   INTERACTION WITH MTA1.
RX   PubMed=21965678; DOI=10.1074/jbc.M111.267237;
RA   Cong L., Pakala S.B., Ohshiro K., Li D.Q., Kumar R.;
RT   "SUMOylation and SUMO-interacting motif (SIM) of metastasis tumor
RT   antigen 1 (MTA1) synergistically regulate its transcriptional
RT   repressor function.";
RL   J. Biol. Chem. 286:43793-43808(2011).
RN   [40]
RP   INTERACTION WITH EPSTEIN-BARR VIRUS LMP1.
RX   PubMed=21795333; DOI=10.1128/JVI.05035-11;
RA   Bentz G.L., Whitehurst C.B., Pagano J.S.;
RT   "Epstein-Barr virus latent membrane protein 1 (LMP1) C-terminal-
RT   activating region 3 contributes to LMP1-mediated cellular migration
RT   via its interaction with Ubc9.";
RL   J. Virol. 85:10144-10153(2011).
RN   [41]
RP   SUBCELLULAR LOCATION.
RX   PubMed=22214662; DOI=10.4161/cc.11.2.18999;
RA   Bennett R.L., Pan Y., Christian J., Hui T., May W.S. Jr.;
RT   "The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and
RT   activation, leading to G(1) arrest.";
RL   Cell Cycle 11:407-417(2012).
RN   [42]
RP   PHOSPHORYLATION AT SER-71.
RX   PubMed=22509284; DOI=10.1371/journal.pone.0034250;
RA   Su Y.F., Yang T., Huang H., Liu L.F., Hwang J.;
RT   "Phosphorylation of Ubc9 by Cdk1 enhances SUMOylation activity.";
RL   PLoS ONE 7:E34250-E34250(2012).
RN   [43]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [44]
RP   INTERACTION WITH SETX.
RX   PubMed=24105744; DOI=10.1101/gad.224923.113;
RA   Richard P., Feng S., Manley J.L.;
RT   "A SUMO-dependent interaction between Senataxin and the exosome,
RT   disrupted in the neurodegenerative disease AOA2, targets the exosome
RT   to sites of transcription-induced DNA damage.";
RL   Genes Dev. 27:2227-2232(2013).
RN   [45]
RP   INTERACTION WITH UHRF2.
RX   PubMed=23404503; DOI=10.1074/jbc.M112.438234;
RA   Oh Y., Chung K.C.;
RT   "UHRF2, a ubiquitin E3 ligase, acts as a small ubiquitin-like modifier
RT   E3 ligase for zinc finger protein 131.";
RL   J. Biol. Chem. 288:9102-9111(2013).
RN   [46]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-71, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [47]
RP   INTERACTION WITH NR3C1.
RX   PubMed=23508108; DOI=10.1128/MCB.01470-12;
RA   Druker J., Liberman A.C., Antunica-Noguerol M., Gerez J.,
RA   Paez-Pereda M., Rein T., Iniguez-Lluhi J.A., Holsboer F., Arzt E.;
RT   "RSUME enhances glucocorticoid receptor SUMOylation and
RT   transcriptional activity.";
RL   Mol. Cell. Biol. 33:2116-2127(2013).
RN   [48]
RP   INTERACTION WITH RWDD3.
RX   PubMed=23469069; DOI=10.1371/journal.pone.0057795;
RA   Gerez J., Fuertes M., Tedesco L., Silberstein S., Sevlever G.,
RA   Paez-Pereda M., Holsboer F., Turjanski A.G., Arzt E.;
RT   "In silico structural and functional characterization of the RSUME
RT   splice variants.";
RL   PLoS ONE 8:E57795-E57795(2013).
RN   [49]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [50]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-49, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [51]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-49, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [52]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-49, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [53]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-48 AND LYS-49, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.O114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to
RT   replication stress reveals novel small ubiquitin-like modified target
RT   proteins and acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [54]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [55]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS).
RX   PubMed=9261152; DOI=10.1074/jbc.272.34.21381;
RA   Tong H., Hateboer G., Perrakis A., Bernards R., Sixma T.K.;
RT   "Crystal structure of murine/human Ubc9 provides insight into the
RT   variability of the ubiquitin-conjugating system.";
RL   J. Biol. Chem. 272:21381-21387(1997).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) IN COMPLEX WITH RANGAP1.
RX   PubMed=11853669; DOI=10.1016/S0092-8674(02)00630-X;
RA   Bernier-Villamor V., Sampson D.A., Matunis M.J., Lima C.D.;
RT   "Structural basis for E2-mediated SUMO conjugation revealed by a
RT   complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1.";
RL   Cell 108:345-356(2002).
RN   [57]
RP   X-RAY CRYSTALLOGRAPHY (3.01 ANGSTROMS) IN COMPLEX WITH SUMO1; RANGAP1
RP   AND RANBP2.
RX   PubMed=15931224; DOI=10.1038/nature03588;
RA   Reverter D., Lima C.D.;
RT   "Insights into E3 ligase activity revealed by a SUMO-RanGAP1-Ubc9-
RT   Nup358 complex.";
RL   Nature 435:687-692(2005).
RN   [58]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) IN COMPLEX WITH RANGAP1, AND
RP   MUTAGENESIS OF ASN-85; TYR-87 AND ASP-127.
RX   PubMed=16732283; DOI=10.1038/nsmb1104;
RA   Yunus A.A., Lima C.D.;
RT   "Lysine activation and functional analysis of E2-mediated conjugation
RT   in the SUMO pathway.";
RL   Nat. Struct. Mol. Biol. 13:491-499(2006).
RN   [59]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) IN COMPLEX WITH SUMO1,
RP   INTERACTION WITH SUMO1; SUMO2 AND SUMO3, AND FUNCTION.
RX   PubMed=17466333; DOI=10.1016/j.jmb.2007.04.006;
RA   Capili A.D., Lima C.D.;
RT   "Structure and analysis of a complex between SUMO and Ubc9 illustrates
RT   features of a conserved E2-Ubl interaction.";
RL   J. Mol. Biol. 369:608-618(2007).
RN   [60]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) IN COMPLEX WITH NFATC2IP/NIP45,
RP   INTERACTION WITH NFATC2IP, AND FUNCTION.
RX   PubMed=20077568; DOI=10.1002/prot.22667;
RA   Sekiyama N., Arita K., Ikeda Y., Hashiguchi K., Ariyoshi M.,
RA   Tochio H., Saitoh H., Shirakawa M.;
RT   "Structural basis for regulation of poly-SUMO chain by a SUMO-like
RT   domain of Nip45.";
RL   Proteins 78:1491-1502(2010).
RN   [61]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) IN COMPLEX WITH IPO13.
RX   PubMed=21139563; DOI=10.1038/emboj.2010.320;
RA   Grunwald M., Bono F.;
RT   "Structure of Importin13-Ubc9 complex: nuclear import and release of a
RT   key regulator of sumoylation.";
RL   EMBO J. 30:427-438(2011).
RN   [62]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) IN COMPLEX WITH RWDD3, AND
RP   INTERACTION WITH RWDD3.
RX   PubMed=25918163; DOI=10.1074/jbc.M115.644047;
RA   Alontaga A.Y., Ambaye N.D., Li Y.J., Vega R., Chen C.H., Bzymek K.P.,
RA   Williams J.C., Hu W., Chen Y.;
RT   "RWD domain as an E2 (Ubc9)-interaction module.";
RL   J. Biol. Chem. 290:16550-16559(2015).
RN   [63]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) IN COMPLEX WITH ZNF451 AND
RP   SUMO2, FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND INTERACTION WITH
RP   ZNF451 AND SUMO2.
RX   PubMed=26524494; DOI=10.1038/nsmb.3116;
RA   Cappadocia L., Pichler A., Lima C.D.;
RT   "Structural basis for catalytic activation by the human ZNF451 SUMO E3
RT   ligase.";
RL   Nat. Struct. Mol. Biol. 22:968-975(2015).
CC   -!- FUNCTION: Accepts the ubiquitin-like proteins SUMO1, SUMO2, SUMO3
CC       and SUMO4 from the UBLE1A-UBLE1B E1 complex and catalyzes their
CC       covalent attachment to other proteins with the help of an E3
CC       ligase such as RANBP2, CBX4 and ZNF451. Can catalyze the formation
CC       of poly-SUMO chains. Necessary for sumoylation of FOXL2 and KAT5.
CC       Essential for nuclear architecture and chromosome segregation.
CC       Sumoylates p53/TP53 at 'Lys-386'. {ECO:0000269|PubMed:11451954,
CC       ECO:0000269|PubMed:15809060, ECO:0000269|PubMed:17466333,
CC       ECO:0000269|PubMed:19638400, ECO:0000269|PubMed:19744555,
CC       ECO:0000269|PubMed:20077568, ECO:0000269|PubMed:26524494,
CC       ECO:0000269|PubMed:8668529}.
CC   -!- CATALYTIC ACTIVITY: SUMOyl-[E2 SUMO-conjugating enzyme]-L-cysteine
CC       + [acceptor-protein]-L-lysine = [E2 SUMO-conjugating enzyme]-L-
CC       cysteine + N(6)-SUMOyl-[acceptor protein]-L-lysine.
CC       {ECO:0000269|PubMed:26524494}.
CC   -!- PATHWAY: Protein modification; protein sumoylation.
CC       {ECO:0000269|PubMed:26524494}.
CC   -!- SUBUNIT: Interacts with SETX (PubMed:24105744). Interacts with
CC       HIPK1, HIPK2, PPM1J, RASD2 and TCF3 Interacts with NR2C1; the
CC       interaction promotes its sumoylation (By similarity). Forms a
CC       tight complex with RANGAP1 and RANBP2. Interacts with SIAH1 and
CC       PARP. Interacts with various transcription factors such as TFAP2A,
CC       TFAP2B, TFAP2C, AR, ETS1 and SOX4. Interacts with RWDD3; the
CC       interaction enhances the sumoylation of a number of proteins such
CC       as HIF1A and I-kappa-B. Interacts with DNMT1. Interacts with
CC       FOXL2. Forms a complex with SENP6 and UBE2I in response to UV
CC       irradiation. Interacts with human herpesvirus 6 IE2. Interacts
CC       with human adenovirus early E1A protein; this interaction
CC       interferes with polysumoylation (Probable). Interacts with DNM1l
CC       (via its GTPase and B domains); the interaction promotes
CC       sumoylation of DNM1L, mainly in its B domain. Interacts with PML-
CC       RARA oncoprotein (via the coiled-colied domain); the interaction
CC       is required for sumoylation of the PML-RARA oncoprotein. Interacts
CC       with IPO13. Interacts with NFATC2IP; this inhibits formation of
CC       poly-SUMO chains. Interacts with FHIT. Interacts with PRKRA and
CC       p53/TP53 (By similarity). Interacts with UHRF2. Interacts with
CC       NR3C1 and this interaction is enhanced in the presence of RWDD3.
CC       Interacts with MTA1. Interacts with ZNF451. Identified in a
CC       complex with SUMO2 and UBC9, where one ZNF451 interacts with one
CC       UBC9 and two SUMO2 chains, one bound to the UBC9 active site and
CC       the other to another region of the same UBC9 molecule. Interacts
CC       with Epstein-barr virus protein LMP1. Interacts with CPEB3 (By
CC       similarity). {ECO:0000250|UniProtKB:P63280,
CC       ECO:0000269|PubMed:10383460, ECO:0000269|PubMed:11085938,
CC       ECO:0000269|PubMed:11853669, ECO:0000269|PubMed:12072434,
CC       ECO:0000269|PubMed:12924945, ECO:0000269|PubMed:15378033,
CC       ECO:0000269|PubMed:15608651, ECO:0000269|PubMed:15809060,
CC       ECO:0000269|PubMed:15931224, ECO:0000269|PubMed:16631117,
CC       ECO:0000269|PubMed:16732283, ECO:0000269|PubMed:17005699,
CC       ECO:0000269|PubMed:17466333, ECO:0000269|PubMed:17956732,
CC       ECO:0000269|PubMed:19450230, ECO:0000269|PubMed:19638400,
CC       ECO:0000269|PubMed:19744555, ECO:0000269|PubMed:20077568,
CC       ECO:0000269|PubMed:20543865, ECO:0000269|PubMed:21139563,
CC       ECO:0000269|PubMed:21795333, ECO:0000269|PubMed:21965678,
CC       ECO:0000269|PubMed:23404503, ECO:0000269|PubMed:23469069,
CC       ECO:0000269|PubMed:23508108, ECO:0000269|PubMed:24105744,
CC       ECO:0000269|PubMed:25918163, ECO:0000269|PubMed:26524494,
CC       ECO:0000269|PubMed:8824223, ECO:0000269|PubMed:9197546,
CC       ECO:0000269|PubMed:9334332, ECO:0000305}.
CC   -!- INTERACTION:
CC       G2XKQ0:-; NbExp=3; IntAct=EBI-80168, EBI-10175576;
CC       P29991:- (xeno); NbExp=3; IntAct=EBI-80168, EBI-8826488;
CC       O14503:BHLHE40; NbExp=3; IntAct=EBI-80168, EBI-711810;
CC       Q9H444:CHMP4B; NbExp=3; IntAct=EBI-80168, EBI-749627;
CC       Q9UER7:DAXX; NbExp=3; IntAct=EBI-80168, EBI-77321;
CC       Q9UBC3:DNMT3B; NbExp=3; IntAct=EBI-80168, EBI-80125;
CC       P03116:E1 (xeno); NbExp=2; IntAct=EBI-80168, EBI-7015985;
CC       Q8WWZ3:EDARADD; NbExp=3; IntAct=EBI-80168, EBI-2949647;
CC       P19419:ELK1; NbExp=7; IntAct=EBI-80168, EBI-726632;
CC       Q96IK5:GMCL1; NbExp=4; IntAct=EBI-80168, EBI-2548508;
CC       Q08379:GOLGA2; NbExp=3; IntAct=EBI-80168, EBI-618309;
CC       P56524:HDAC4; NbExp=3; IntAct=EBI-80168, EBI-308629;
CC       O94829:IPO13; NbExp=6; IntAct=EBI-80168, EBI-747310;
CC       P03230:LMP1 (xeno); NbExp=5; IntAct=EBI-80168, EBI-6973030;
CC       O75928:PIAS2; NbExp=8; IntAct=EBI-80168, EBI-348555;
CC       P46060:RANGAP1; NbExp=6; IntAct=EBI-80168, EBI-396091;
CC       Q6ZNA4:RNF111; NbExp=5; IntAct=EBI-80168, EBI-2129175;
CC       Q9Y3V2:RWDD3; NbExp=5; IntAct=EBI-80168, EBI-1549885;
CC       Q7Z333:SETX; NbExp=3; IntAct=EBI-80168, EBI-1220123;
CC       Q13485:SMAD4; NbExp=4; IntAct=EBI-80168, EBI-347263;
CC       P56693:SOX10; NbExp=2; IntAct=EBI-80168, EBI-1167533;
CC       P63165:SUMO1; NbExp=6; IntAct=EBI-80168, EBI-80140;
CC       P61956:SUMO2; NbExp=6; IntAct=EBI-80168, EBI-473220;
CC       P05549:TFAP2A; NbExp=4; IntAct=EBI-80168, EBI-347351;
CC       Q92754:TFAP2C; NbExp=5; IntAct=EBI-80168, EBI-937309;
CC       Q12800:TFCP2; NbExp=4; IntAct=EBI-80168, EBI-717422;
CC       P22314:UBA1; NbExp=2; IntAct=EBI-80168, EBI-709688;
CC       Q9HCK0:ZBTB26; NbExp=3; IntAct=EBI-80168, EBI-3918996;
CC       Q8N3Z6:ZCCHC7; NbExp=3; IntAct=EBI-80168, EBI-7265024;
CC       Q9Y4E5:ZNF451; NbExp=3; IntAct=EBI-80168, EBI-747230;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Mainly nuclear. In
CC       spermatocytes, localizes in synaptonemal complexes. Recruited by
CC       BCL11A into the nuclear body (By similarity). {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed in heart, skeletal muscle, pancreas,
CC       kidney, liver, lung, placenta and brain. Also expressed in testis
CC       and thymus. {ECO:0000269|PubMed:8610150}.
CC   -!- PTM: Phosphorylation at Ser-71 significantly enhances SUMOylation
CC       activity. {ECO:0000269|PubMed:22509284}.
CC   -!- SIMILARITY: Belongs to the ubiquitin-conjugating enzyme family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00388}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH51289.3; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=BAD92225.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X96427; CAA65287.1; -; mRNA.
DR   EMBL; U45328; AAA86662.1; -; mRNA.
DR   EMBL; D45050; BAA08091.1; -; mRNA.
DR   EMBL; U29092; AAC51361.1; -; mRNA.
DR   EMBL; U31933; AAB02181.1; -; mRNA.
DR   EMBL; U31882; AAC50603.1; -; mRNA.
DR   EMBL; U66867; AAC50716.1; -; mRNA.
DR   EMBL; U66818; AAC50715.1; -; mRNA.
DR   EMBL; U38785; AAB09410.1; -; mRNA.
DR   EMBL; AJ002385; CAA05359.1; -; mRNA.
DR   EMBL; BT006932; AAP35578.1; -; mRNA.
DR   EMBL; AB208988; BAD92225.1; ALT_INIT; mRNA.
DR   EMBL; AE006466; AAK61274.1; -; Genomic_DNA.
DR   EMBL; AL031714; CAB45853.1; -; Genomic_DNA.
DR   EMBL; CH471112; EAW85673.1; -; Genomic_DNA.
DR   EMBL; CH471112; EAW85676.1; -; Genomic_DNA.
DR   EMBL; CH471112; EAW85677.1; -; Genomic_DNA.
DR   EMBL; CH471112; EAW85678.1; -; Genomic_DNA.
DR   EMBL; CH471112; EAW85679.1; -; Genomic_DNA.
DR   EMBL; BC000427; AAH00427.1; -; mRNA.
DR   EMBL; BC004429; AAH04429.1; -; mRNA.
DR   EMBL; BC051289; AAH51289.3; ALT_INIT; mRNA.
DR   CCDS; CCDS10433.1; -.
DR   PIR; JC6056; JC6056.
DR   RefSeq; NP_003336.1; NM_003345.4.
DR   RefSeq; NP_919235.1; NM_194259.2.
DR   RefSeq; NP_919236.1; NM_194260.2.
DR   RefSeq; NP_919237.1; NM_194261.2.
DR   RefSeq; XP_016879129.1; XM_017023640.1.
DR   UniGene; Hs.302903; -.
DR   PDB; 1A3S; X-ray; 2.80 A; A=1-158.
DR   PDB; 1KPS; X-ray; 2.50 A; A/C=1-158.
DR   PDB; 1Z5Q; Model; -; A=1-158.
DR   PDB; 1Z5S; X-ray; 3.01 A; A=1-158.
DR   PDB; 2GRN; X-ray; 1.80 A; A=1-158.
DR   PDB; 2GRO; X-ray; 1.70 A; A=1-158.
DR   PDB; 2GRP; X-ray; 2.05 A; A=1-158.
DR   PDB; 2GRQ; X-ray; 1.70 A; A=1-158.
DR   PDB; 2GRR; X-ray; 1.30 A; A=1-158.
DR   PDB; 2O25; X-ray; 2.60 A; C/D=1-158.
DR   PDB; 2PE6; X-ray; 2.40 A; A=1-158.
DR   PDB; 2PX9; NMR; -; B=1-158.
DR   PDB; 2XWU; X-ray; 2.80 A; A=1-158.
DR   PDB; 3A4S; X-ray; 2.70 A; A/B=1-158.
DR   PDB; 3UIN; X-ray; 2.60 A; A=1-158.
DR   PDB; 3UIO; X-ray; 2.60 A; A=1-158.
DR   PDB; 3UIP; X-ray; 2.29 A; A=1-158.
DR   PDB; 4W5V; X-ray; 2.50 A; A=1-158.
DR   PDB; 4Y1L; X-ray; 2.70 A; A/B=1-158.
DR   PDB; 5D2M; X-ray; 2.40 A; A/D=1-158.
DR   PDB; 5F6D; X-ray; 1.55 A; A=2-158.
DR   PDB; 5F6E; X-ray; 1.12 A; A=2-158.
DR   PDB; 5F6U; X-ray; 1.55 A; A=2-158.
DR   PDB; 5F6V; X-ray; 1.49 A; A=2-158.
DR   PDB; 5F6W; X-ray; 1.70 A; A=2-158.
DR   PDB; 5F6X; X-ray; 1.56 A; A=2-158.
DR   PDB; 5F6Y; X-ray; 1.14 A; A=2-158.
DR   PDB; 5FQ2; X-ray; 2.20 A; A=1-158.
DR   PDBsum; 1A3S; -.
DR   PDBsum; 1KPS; -.
DR   PDBsum; 1Z5Q; -.
DR   PDBsum; 1Z5S; -.
DR   PDBsum; 2GRN; -.
DR   PDBsum; 2GRO; -.
DR   PDBsum; 2GRP; -.
DR   PDBsum; 2GRQ; -.
DR   PDBsum; 2GRR; -.
DR   PDBsum; 2O25; -.
DR   PDBsum; 2PE6; -.
DR   PDBsum; 2PX9; -.
DR   PDBsum; 2XWU; -.
DR   PDBsum; 3A4S; -.
DR   PDBsum; 3UIN; -.
DR   PDBsum; 3UIO; -.
DR   PDBsum; 3UIP; -.
DR   PDBsum; 4W5V; -.
DR   PDBsum; 4Y1L; -.
DR   PDBsum; 5D2M; -.
DR   PDBsum; 5F6D; -.
DR   PDBsum; 5F6E; -.
DR   PDBsum; 5F6U; -.
DR   PDBsum; 5F6V; -.
DR   PDBsum; 5F6W; -.
DR   PDBsum; 5F6X; -.
DR   PDBsum; 5F6Y; -.
DR   PDBsum; 5FQ2; -.
DR   ProteinModelPortal; P63279; -.
DR   SMR; P63279; -.
DR   BioGrid; 113177; 458.
DR   DIP; DIP-29078N; -.
DR   IntAct; P63279; 189.
DR   MINT; MINT-137807; -.
DR   STRING; 9606.ENSP00000324897; -.
DR   BindingDB; P63279; -.
DR   ChEMBL; CHEMBL1741191; -.
DR   TCDB; 3.A.20.1.1; the peroxisomal protein importer (ppi) family.
DR   iPTMnet; P63279; -.
DR   PhosphoSitePlus; P63279; -.
DR   SwissPalm; P63279; -.
DR   BioMuta; UBE2I; -.
DR   DMDM; 54039791; -.
DR   EPD; P63279; -.
DR   MaxQB; P63279; -.
DR   PaxDb; P63279; -.
DR   PeptideAtlas; P63279; -.
DR   PRIDE; P63279; -.
DR   TopDownProteomics; P63279; -.
DR   DNASU; 7329; -.
DR   Ensembl; ENST00000325437; ENSP00000324897; ENSG00000103275.
DR   Ensembl; ENST00000355803; ENSP00000348056; ENSG00000103275.
DR   Ensembl; ENST00000397514; ENSP00000380649; ENSG00000103275.
DR   Ensembl; ENST00000397515; ENSP00000380650; ENSG00000103275.
DR   Ensembl; ENST00000403747; ENSP00000385009; ENSG00000103275.
DR   Ensembl; ENST00000406620; ENSP00000384568; ENSG00000103275.
DR   Ensembl; ENST00000566587; ENSP00000457064; ENSG00000103275.
DR   GeneID; 7329; -.
DR   KEGG; hsa:7329; -.
DR   UCSC; uc002clc.2; human.
DR   CTD; 7329; -.
DR   DisGeNET; 7329; -.
DR   GeneCards; UBE2I; -.
DR   HGNC; HGNC:12485; UBE2I.
DR   HPA; CAB009021; -.
DR   HPA; HPA003909; -.
DR   MIM; 601661; gene.
DR   neXtProt; NX_P63279; -.
DR   OpenTargets; ENSG00000103275; -.
DR   PharmGKB; PA37134; -.
DR   eggNOG; KOG0424; Eukaryota.
DR   eggNOG; COG5078; LUCA.
DR   GeneTree; ENSGT00550000075088; -.
DR   HOGENOM; HOG000233454; -.
DR   HOVERGEN; HBG063308; -.
DR   InParanoid; P63279; -.
DR   KO; K10577; -.
DR   OMA; DLKRWEC; -.
DR   PhylomeDB; P63279; -.
DR   TreeFam; TF101122; -.
DR   Reactome; R-HSA-1221632; Meiotic synapsis.
DR   Reactome; R-HSA-3065678; SUMO is transferred from E1 to E2 (UBE2I, UBC9).
DR   Reactome; R-HSA-3108214; SUMOylation of DNA damage response and repair proteins.
DR   Reactome; R-HSA-3232118; SUMOylation of transcription factors.
DR   Reactome; R-HSA-4551638; SUMOylation of chromatin organization proteins.
DR   Reactome; R-HSA-4570464; SUMOylation of RNA binding proteins.
DR   Reactome; R-HSA-4615885; SUMOylation of DNA replication proteins.
DR   Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks.
DR   Reactome; R-HSA-5693607; Processing of DNA double-strand break ends.
DR   Reactome; R-HSA-5696395; Formation of Incision Complex in GG-NER.
DR   Reactome; R-HSA-8866904; Negative regulation of activity of TFAP2 (AP-2) family transcription factors.
DR   SignaLink; P63279; -.
DR   SIGNOR; P63279; -.
DR   UniPathway; UPA00886; -.
DR   ChiTaRS; UBE2I; human.
DR   EvolutionaryTrace; P63279; -.
DR   GeneWiki; UBE2I; -.
DR   GenomeRNAi; 7329; -.
DR   PRO; PR:P63279; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000103275; -.
DR   CleanEx; HS_UBE2I; -.
DR   ExpressionAtlas; P63279; baseline and differential.
DR   Genevisible; P63279; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005635; C:nuclear envelope; TAS:Reactome.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IDA:UniProtKB.
DR   GO; GO:1990356; C:sumoylated E2 ligase complex; IDA:CAFA.
DR   GO; GO:0000795; C:synaptonemal complex; TAS:ProtInc.
DR   GO; GO:1990234; C:transferase complex; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0043398; F:HLH domain binding; IEA:Ensembl.
DR   GO; GO:0071535; F:RING-like zinc finger domain binding; IPI:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0044388; F:small protein activating enzyme binding; IPI:CAFA.
DR   GO; GO:0061656; F:SUMO conjugating enzyme activity; IDA:BHF-UCL.
DR   GO; GO:0019789; F:SUMO transferase activity; EXP:Reactome.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0006464; P:cellular protein modification process; TAS:ProtInc.
DR   GO; GO:0007059; P:chromosome segregation; IEA:UniProtKB-KW.
DR   GO; GO:0070911; P:global genome nucleotide-excision repair; TAS:Reactome.
DR   GO; GO:0007067; P:mitotic nuclear division; IEA:UniProtKB-KW.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:BHF-UCL.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IEA:Ensembl.
DR   GO; GO:1903755; P:positive regulation of SUMO transferase activity; IDA:BHF-UCL.
DR   GO; GO:0016925; P:protein sumoylation; IDA:UniProtKB.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; TAS:ProtInc.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   CDD; cd00195; UBCc; 1.
DR   Gene3D; 3.10.110.10; -; 1.
DR   InterPro; IPR027230; Ubc9.
DR   InterPro; IPR000608; UBQ-conjugat_E2.
DR   InterPro; IPR023313; UBQ-conjugating_AS.
DR   InterPro; IPR016135; UBQ-conjugating_enzyme/RWD.
DR   PANTHER; PTHR24067:SF164; PTHR24067:SF164; 1.
DR   Pfam; PF00179; UQ_con; 1.
DR   SUPFAM; SSF54495; SSF54495; 1.
DR   PROSITE; PS00183; UBIQUITIN_CONJUGAT_1; 1.
DR   PROSITE; PS50127; UBIQUITIN_CONJUGAT_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Cell cycle; Cell division;
KW   Chromosome partition; Complete proteome; Cytoplasm;
KW   Host-virus interaction; Isopeptide bond; Mitosis; Nucleotide-binding;
KW   Nucleus; Phosphoprotein; Reference proteome; Transferase;
KW   Ubl conjugation; Ubl conjugation pathway.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22814378}.
FT   CHAIN         2    158       SUMO-conjugating enzyme UBC9.
FT                                /FTId=PRO_0000082454.
FT   REGION       13     18       Interaction with SUMO1.
FT   ACT_SITE     93     93       Glycyl thioester intermediate.
FT   SITE          4      4       Interaction with RANBP2.
FT   SITE         25     25       Interaction with RANBP2.
FT   SITE         57     57       Interaction with RANBP2.
FT   SITE        100    101       Substrate binding.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22814378}.
FT   MOD_RES      65     65       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES      71     71       Phosphoserine; by CDK1.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:22509284}.
FT   CROSSLNK     18     18       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   CROSSLNK     48     48       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25755297}.
FT   CROSSLNK     49     49       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1).
FT                                {ECO:0000244|PubMed:25114211}.
FT   CROSSLNK     49     49       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25114211,
FT                                ECO:0000244|PubMed:25218447,
FT                                ECO:0000244|PubMed:25755297,
FT                                ECO:0000244|PubMed:25772364}.
FT   MUTAGEN      13     14       RK->AA: Impairs binding to SUMO1 and
FT                                catalytic activity.
FT                                {ECO:0000269|PubMed:12924945}.
FT   MUTAGEN      17     18       RK->AA: Impairs binding to SUMO1 and
FT                                catalytic activity.
FT                                {ECO:0000269|PubMed:12924945}.
FT   MUTAGEN      22     22       F->A: Impairs binding to RANBP2.
FT                                {ECO:0000269|PubMed:15608651}.
FT   MUTAGEN      25     25       V->A: Impairs binding to RANBP2.
FT                                {ECO:0000269|PubMed:15608651}.
FT   MUTAGEN      27     27       V->A: Impairs binding to RANBP2.
FT                                {ECO:0000269|PubMed:15608651}.
FT   MUTAGEN      42     42       E->A: Slightly impairs binding to RANBP2.
FT                                {ECO:0000269|PubMed:15608651}.
FT   MUTAGEN      48     48       K->A: Slightly impairs binding to RANBP2.
FT                                {ECO:0000269|PubMed:15608651}.
FT   MUTAGEN      54     54       E->A: Slightly impairs binding to RANBP2.
FT                                {ECO:0000269|PubMed:15608651}.
FT   MUTAGEN      57     57       L->A: Impairs binding to RANBP2.
FT                                {ECO:0000269|PubMed:15608651}.
FT   MUTAGEN      59     59       K->A: Impairs binding to RANBP2.
FT                                {ECO:0000269|PubMed:15608651}.
FT   MUTAGEN      61     61       R->A: Slightly impairs binding to RANBP2.
FT                                {ECO:0000269|PubMed:15608651}.
FT   MUTAGEN      85     85       N->Q: Impairs catalytic activity.
FT                                {ECO:0000269|PubMed:16732283}.
FT   MUTAGEN      87     87       Y->A: Impairs catalytic activity.
FT                                {ECO:0000269|PubMed:16732283}.
FT   MUTAGEN      93     93       C->S: Loss of enhancement of sumoylation
FT                                by RWDD3. No effect on RWDD3 protein
FT                                levels.
FT   MUTAGEN     100    101       DK->AA: Impairs catalytic activity.
FT                                {ECO:0000269|PubMed:12641448}.
FT   MUTAGEN     127    127       D->A: Impairs catalytic activity.
FT                                {ECO:0000269|PubMed:16732283}.
FT   MUTAGEN     127    127       D->S: No effect on catalytic activity.
FT                                {ECO:0000269|PubMed:16732283}.
FT   CONFLICT     18     18       K -> P (in Ref. 6; AAC50603).
FT                                {ECO:0000305}.
FT   CONFLICT     86     89       VYPS -> GVPF (in Ref. 6; AAC50603).
FT                                {ECO:0000305}.
FT   HELIX         3     18       {ECO:0000244|PDB:5F6E}.
FT   STRAND       25     30       {ECO:0000244|PDB:5F6E}.
FT   STRAND       32     34       {ECO:0000244|PDB:2PE6}.
FT   STRAND       36     46       {ECO:0000244|PDB:5F6E}.
FT   TURN         52     55       {ECO:0000244|PDB:5F6E}.
FT   STRAND       57     63       {ECO:0000244|PDB:5F6E}.
FT   TURN         66     69       {ECO:0000244|PDB:5F6E}.
FT   STRAND       74     79       {ECO:0000244|PDB:5F6E}.
FT   STRAND       90     92       {ECO:0000244|PDB:5F6E}.
FT   HELIX        95     97       {ECO:0000244|PDB:5F6E}.
FT   TURN         99    102       {ECO:0000244|PDB:5F6E}.
FT   HELIX       109    121       {ECO:0000244|PDB:5F6E}.
FT   HELIX       131    139       {ECO:0000244|PDB:5F6E}.
FT   HELIX       141    154       {ECO:0000244|PDB:5F6E}.
SQ   SEQUENCE   158 AA;  18007 MW;  E2C826E9C8D0683D CRC64;
     MSGIALSRLA QERKAWRKDH PFGFVAVPTK NPDGTMNLMN WECAIPGKKG TPWEGGLFKL
     RMLFKDDYPS SPPKCKFEPP LFHPNVYPSG TVCLSILEED KDWRPAITIK QILLGIQELL
     NEPNIQDPAQ AEAYTIYCQN RVEYEKRVRA QAKKFAPS
//
